Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

We will not know for sure until the Brilacidin for Covid19 protocol is released {? tomorrow} but the last PR is suggestive of a plan similar to NIAID's ACTT plan which tested Remdesivir and other Covid drugs.

Plus the most of the recent Covid therapeutic studies have been done through one of the 6 ACTT plans.

https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials#activ6

"After an interim review, by an independent Data Monitoring Committee (DMC), dosing may be extended to 5 days.

The trial’s primary endpoint is time to sustained recovery through Day 29, using a clinical status ordinal scale based on that used in the series of National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trials (ACTTs). Additional endpoints include: in-hospital outcomes (e.g., duration of hospitalization, time to discharge), all-cause mortality, measurement of disease biomarkers (e.g., CRP, ferritin) and inflammation-related biomarkers (e.g., IL-1ß, IL-6, IL-10, total IL-18, TNF-a), changes to SARS-CoV-2 viral load, as well as other key measures."

http://www.ipharminc.com/press-release/2021/2/26/innovation-pharma-provides-study-details-for-ongoing-phase-2-clinical-trial-of-brilacidin-in-hospitalized-covid-19-patients

Glta, Farrell